Lannett has entered into an exclusive U.S. distribution agreement for Respirent Pharmaceuticals’ generic of GSK’s Flovent Diskus (fluticasone propionate powder inhaler). According to the Orange Book, ...

PHILADELPHIA, Aug. 17, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent ...

Please provide your email address to receive an email when new articles are posted on . For approval, generic fluticasone-salmeterol was required to be tested in only patients with asthma, not COPD.

Fluticasone propionate 50mcg/inh, 100mcg/inh, 250mcg/inh; dry pwd for inhalation; blisters with inhalation device; contains lactose monohydrate. as a disposable orange plastic inhaler containing a ...

A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score-matched ...

A total of 332 patients entered the study and 277 patients were randomised and treated, 137 with FP250µg twice daily via Diskus TM inhaler and 140 with budesonide 600µg twice daily via Turbuhaler TM.

Please provide your email address to receive an email when new articles are posted on . The FDA recently issued approval to the first generic version of ...

Vectura's partner Hikma has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder), in dosage strengths of 100mcg/50mcg and ...

PHILADELPHIA, June 1, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for ...

Flovent, a popular corticosteroid inhaler used to treat asthma, is no longer available. The global manufacturer, Glaxo Smith Kline (GSK), announced in May that the medications — Flovent HFA, a metered ...

The Towards a Revolution in COPD Health (TORCH) trial evaluated the effect of treatments for chronic obstructive pulmonary disease (COPD) on morbidity and mortality outcomes. The study randomized ...